Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)
AssigneeBaylor Research Institute
InventorsJacques F. Banchereau, Sangkon Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
Claims18
A method for increasing the effectiveness of antigen presentation comprising the step of isolating and purifying a DC-ASGPR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
A method for increasing the effectiveness of antigen presentation by dendritic cells comprising binding a DC-ASGPR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
The use of antibodies or other specific binding molecules directed to DC-ASGPR for delivering antigens to antigen-presenting cells for the purpose of eliciting protective or therapeutic immune responses.
The use of antigen-targeting reagents specific to DC-ASGPR for vaccination via the skin.
The use of antigen-targeting reagents specific to DC-ASGPR in association with co-administered or linked adjuvant for vaccination.
The use for antigen-targeting (vaccination) purposes of specific antigens which can be expressed as recombinant antigen-antibody fusion proteins.
A method for increasing the effectiveness of dendritic cells comprising:
- isolating patient dendritic cells
- exposing the dendritic cells to activating amounts of anti-DC-ASGPR antibodies or fragments thereof and antigen to form antigen-loaded, activated dendritic cells;
- and
- reintroducing the antigen-loaded, activated dendritic cells into the patient.
Use of agents that engage DC-ASGPR, alone or with co-activating agents, to activate antigen-presenting cells for therapeutic or protective applications.
Use of anti-DC-ASGPR agents linked to toxic agents for therapeutic purposes in the context of diseases known or suspected to result from inappropriate activation of immune cells via DC-ASGPR.
Dependencies are inferred from the claim text.